Chapter 13. Genetic Targeting of Retroviral Vectors
- David T. Curiel M.D. and
- Joanne T. Douglas Ph.D.
Published Online: 31 MAR 2003
Copyright © 2002 John Wiley & Sons, Inc.
Vector Targeting for Therapeutic Gene Delivery
How to Cite
Dingli, D. and Russell, S. J. (2003) Genetic Targeting of Retroviral Vectors, in Vector Targeting for Therapeutic Gene Delivery (eds D. T. Curiel and J. T. Douglas), John Wiley & Sons, Inc., Hoboken, NJ, USA. doi: 10.1002/0471234303.ch13
Division of Human Gene Therapy, Departments of Medicine, Pathology and Surgery, and the Gene Therapy Center, The University of Alabama at Birmingham, USA
- Published Online: 31 MAR 2003
- Published Print: 9 AUG 2002
Print ISBN: 9780471434795
Online ISBN: 9780471234302
- virus entry and membrane glycoproteins
Vector targeting for specific and efficient transduction of target cells is a major goal of gene therapy. Retroviruses enter mammalian cells by interacting with cell surface receptors that trigger conformational changes in the viral surface envelope glycoproteins leading to membrane fusion and cell entry. Several different retroviral envelope glycoproteins have been shown to tolerate the insertion of polypeptide ligands, such as single chain antibodies, that specify attachment to alternative cell surface receptors. However, after redirecting virus attachment, chimeric envelope glycoproteins often fail to trigger membrane fusion and may furthermore actively interfere with productive infection. In this chapter we summarise the history and status of retrovirus targeting research with emphasis on the targeting strategies that have been recently developed to overcome previous obstacles.